China’s pharmaceutical 3D Printer market size will reach 252 million US dollars in 2024

On May 13, Frost & Sullivan released the “Pharmaceutical 3D Printer Industry Report” (hereinafter referred to as the “Report”). The “Report” shows that there are currently more than 50 companies and institutions in the world that have entered the field of pharmaceutical 3D printers, including dozens of multinational pharmaceutical companies, and active research institutions and companies are mainly located in Europe, the United States and China. The “Report” pointed out that 3D Printer technology has the following three main advantages: precise control of drug release to meet a variety of clinical needs; with high flexibility, it can realize personalized medicine; simple production process, great potential for on-demand manufacturing.

A few days ago, One Think Tank released a report showing that in 2024, the Asia-Pacific region is expected to account for 34.1% of the market share of 3D Printer drugs, with a compound annual growth rate of 18.2%, of which the Chinese market will reach 252 million US dollars.

Source: Zero One Finance